Susanne Sarkar1, Rahul Sarkar1, Thomas Berg1, Martin Schaefer1. 1. Susanne Sarkar, PhD, Department of Psychiatry and Psychotherapy, Charité-Universitätsmedizin Berlin, Campus Charité, Mitte, Berlin, and Department and Outpatient Clinic of Medical Psychology, Center of Psychosocial Medicine, University Medical Center Hamburg-Eppendorf, Hamburg; Rahul Sarkar, MD, Department of Psychiatry and Psychotherapy, Asklepios Westklinikum Hamburg-Klinikum, Hamburg; Thomas Berg, MD, Department of Gastroenterology und Rheumatology, Section of Hepatology, Universitätsklinikum, Leipzig; Martin Schaefer, MD, Department of Psychiatry and Psychotherapy, Charité-Universitätsmedizin Berlin, Campus Charité, Mitte, Berlin, and Department of Psychiatry, Psychotherapy and Addiction Medicine, Kliniken Essen-Mitte, Essen, Germany.
Abstract
BACKGROUND:Antiviral therapy with interferon-alpha (IFN-α) for hepatitis C virus (HCV) infection is associated with increased risk for depression. AIMS: To identify clinical predictors for IFN-α-induced depression during antiviral therapy for HCV infection. METHOD:Depression (defined with the Montgomery-Åsberg Depression Rating Scale (MADRS)) was evaluated before and during antiviral treatment in 91 people with chronic HCV infection without a history of psychiatric disorders. Cognitive function was evaluated using the Trail Making Test A/B (TMT A/B). (Trial registration at ClinicalTrials.gov: NCT00136318.) RESULTS:Depression during antiviral therapy was significantly associated with a baseline MADRS score of 3 or higher (P = 0.006). In total, 89% (n = 16) of patients who had a baseline score >0 for the single item sadness developed depression. Poor baseline performance in the TMT A (P = 0.027) and TMT B (P = 0.033) was predictive for severe depression. CONCLUSIONS:Pre-treatment screening for subthreshold depressive and cognitive symptoms will help to identify those at risk for IFN-α-associated depression among patients with chronic hepatitis C. Royal College of Psychiatrists.
RCT Entities:
BACKGROUND: Antiviral therapy with interferon-alpha (IFN-α) for hepatitis C virus (HCV) infection is associated with increased risk for depression. AIMS: To identify clinical predictors for IFN-α-induced depression during antiviral therapy for HCV infection. METHOD:Depression (defined with the Montgomery-Åsberg Depression Rating Scale (MADRS)) was evaluated before and during antiviral treatment in 91 people with chronic HCV infection without a history of psychiatric disorders. Cognitive function was evaluated using the Trail Making Test A/B (TMT A/B). (Trial registration at ClinicalTrials.gov: NCT00136318.) RESULTS:Depression during antiviral therapy was significantly associated with a baseline MADRS score of 3 or higher (P = 0.006). In total, 89% (n = 16) of patients who had a baseline score >0 for the single item sadness developed depression. Poor baseline performance in the TMT A (P = 0.027) and TMT B (P = 0.033) was predictive for severe depression. CONCLUSIONS: Pre-treatment screening for subthreshold depressive and cognitive symptoms will help to identify those at risk for IFN-α-associated depression among patients with chronic hepatitis C. Royal College of Psychiatrists.
Authors: S Sarkar; A Scherwath; L Schirmer; F Schulz-Kindermann; K Neumann; M Kruse; A Dinkel; S Kunze; F Balck; N Kröger; U Koch; A Mehnert Journal: Bone Marrow Transplant Date: 2014-07-07 Impact factor: 5.483
Authors: Montserrat Masip; Laura Tuneu; Neus Pagès; Xavier Torras; Adolfo Gallego; Josep Maria Guardiola; María José Faus; Maria Antònia Mangues Journal: Int J Clin Pharm Date: 2015-08-13
Authors: Leah H Rubin; Yanxun Xu; Philip J Norris; Xuzhi Wang; Raha Dastgheyb; Kathryn C Fitzgerald; Sheila M Keating; Robert C Kaplan; Pauline M Maki; Kathryn Anastos; Gayle Springer; Lorie Benning; Seble Kassaye; Deborah R Gustafson; Victor G Valcour; Dionna W Williams Journal: Front Integr Neurosci Date: 2020-04-24